Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Agree James, an absolutely ridiculous note with false information! Excellent from Elric as usual! But what a shocker from Keyes! I feel for those investors who have sold due to his advice!
I have been made aware that there was a debate about the awards that Opti are nominated for or win and whether they pay for them. So just to be clear I have spoken to SOH about this and Opti do NOT pay for the awards. They are well respected in the industry which are determined by an expert panel. Anyone can look up the awards and panel members. For example the judges for Vitafoods in Asia this time are here:
Https://www.nutraingredientsasia-awards.com/judges/
Slimbiome is up for weight management ingredient of the year in Asia and Opti do not know any of the judges. Opti have done brilliantly to be nominated as they are a small company and the larger companies have a greater network! Let’s hope we win the award!
Just had amazing cholesterol test results after 3 months on Cholbiome X3. My total wasn’t high to begin with: Total 4.9 from 5.4 HDL 1.7 from 1.5 LDL 2.7 from 3.5 Triglycerides 1 stayed the same Cholesterol to HDL Ratio 2.9 from 3.7 - Decrease of 10% overall but even more impressive: - Decrease of 30% in LDL - bad Cholesterol - Increase in HDL - good cholesterol. Amazing product! Very happy with results.
Exponential revenue growth
Optibiotix (LSE: OPTI) is another AIM-listed company. At a share price of 81.5p, its market capitalisation is £70m.
It develops compounds that modify the human microbiome. These compounds help in the prevention and management of chronic lifestyle diseases, including obesity, high cholesterol and diabetes. It’s moved from research and development to inking an impressive 30-odd (and counting) commercial deals with food and pharmaceutical companies.
Ordinarily, I wouldn’t buy a stock trading at more than 10 times sales — required revenue of not less than £7m in Optibiotix’s case, versus actual revenue of just £541,000 in 2018. However, 85% of this was generated in the second half of the year, and we’re in the very early stages of its partners ramping up sales.
Due to the prospect of exponential revenue growth — much of which will drop straight to the bottom line under the company’s licensing business model — this is a rare instance where I’d be prepared to ignore my less than 10 times sales rule. As such, it’s another stock I see as a credible speculative buy.
Https://uk.finance.yahoo.com/news/3-under-radar-healthcare-stocks-072834051.html?guccounter=2
SOH response to Paul Scott: Https://lemminginvestors.blogspot.com/2019/02/optibiotix-health-company-response-to.html?m=1
Hello, someone is obviously reporting my posts and LSE are removing it as they say it cannot be verified. I will stop posting this from now on! Go to other forum if you want this info! Crazy as it is helping other holders!
I don’t care about news or trading updates, if you have done your research here you know all is well. Long term traders will be well rewarded, all im saying is you say the same thing everyday which is a bit boring that’s all! Others have said the same so not just me saying it!
So you think he is going to match every sell with a buy? Silly. Look at the bigger trades in the last few days; they are buys. The volumes are tiny and going down on tiny volume. Revenues are coming thick and fast now, we have broken even, let’s wait and see what happens now!
Boyzee, it’s getting boring that you keep going on about a seller. In the last few days there has been minimal volume. I posted a response from SOH, there is no seller other than the one he matched YSF. People are just trading and top slicing!
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it has entered into a three year distribution agreement with an established and recognised company ("The Company") to exclusively distribute and commercialise OptiBiotix's CE marked medical device, SlimBiome(R) Medical, in Greece and Cyprus. The agreement grants the Company exclusive distribution in Greece and Cyprus and first right of refusal for the Gulf States in return for meeting annual sales targets to retain exclusivity. This agreement follows on from the announcement that SlimBiome(R) was granted medical device status and a CE mark (RNS: 27 November 2018) and the appointment of Nutrilinea S.R.L as a manufacturer (RNS: 29 November 2018). SlimBiome(R) Medical is clinically proven in a number of clinical studies to promote weight loss and will be sold as 30 single dose sachets to pharmacies and clinics in Greece and Cyprus. The Company requires its identity and the terms of the agreement to remain confidential to protect its commercial interests and launch plans therefore no further details can be disclosed. A further announcement will be made in due course. Stephen OHara, Chief Executive of OptiBiotix, commented: "We are pleased to announce this exclusive distribution deal so soon after achieving medical device registration and CE mark for SlimBiome(R) . Even more encouraging is that the Company has placed an early order and expects to make further orders to support a consumer launch in early 2019. We are delighted at the high level of interest we have received in SlimBiome(R) from an industry which recognises the value of protective patents and trademarks, two industry awards, clinical studies demonstrating safety and efficacy, and now a medical device registration and CE mark. These all provide clear differentiation from other weight loss products increasing the likelihood of commercial success. We hope we can continue to convert this interest into substantial revenues in the months and years ahead as we build the sales network for SlimBiome Medical across Europe and beyond."
Muesli pots now available on Opti online store! Https://optibiotix.online/collections/weight-management
SOH today: “If you can reassure investors all is going very well and we would hope to update them with some really good progress shortly. As most experienced investors will know its currently all about market uncertainty and given OptiBiotix shares have performed well over the years its a stock that investors can take profit from in times of uncertainty.”